Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study

BACKGROUND: Sandoz etanercept (SDZ ETN; GP2015) is an etanercept biosimilar with equivalent efficacy and comparable safety and immunogenicity to reference etanercept (ETN) in patients with moderate-to-severe chronic plaque-type psoriasis. METHODS: EQUIRA was a phase III, double-blind study conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaworski, Janusz, Matucci-Cerinic, Marco, Schulze-Koops, Hendrik, Buch, Maya H., Kucharz, Eugeniusz J., Allanore, Yannick, Kavanaugh, Arthur, Young, Philip, Babic, Goran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540397/
https://www.ncbi.nlm.nih.gov/pubmed/31138316
http://dx.doi.org/10.1186/s13075-019-1907-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540397/
https://www.ncbi.nlm.nih.gov/pubmed/31138316
http://dx.doi.org/10.1186/s13075-019-1907-x

Ejemplares similares